{
    "nct_id": "NCT05429632",
    "official_title": "Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod As Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT",
    "inclusion_criteria": "* Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2022 classification of AML and related precursor neoplasm, including AML with myelodysplasia-related gene mutations\n* European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1, or AML of any risk in CR2, [CRi] is also allowable\n* Planned allogeneic HCT from fully matched related or unrelated donor with no more than 1 antigen mismatch or planned use of haploidentical donor using PBSC graft\n* Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5\n* Planned use of CsA-based or TAC-based GvHD prophylaxis\n* age ≥ 18 years and ≤ 75 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Use of anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis\n* Diagnosis of macular edema during screening\n* Cardiac/pulmonary/hepatic/renal dysfunction\n* Hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN); or total bilirubin > 1.5 mg/dL\n* Renal dysfunction with estimated creatinine clearance < 45 mL/min by the Cockcroft-Gault formula",
    "miscellaneous_criteria": ""
}